Search results
Search for "lecithin" in Full Text gives 5 result(s) in Beilstein Journal of Organic Chemistry.
Synthesis of ether lipids: natural compounds and analogues
- Marco Antônio G. B. Gomes,
- Alicia Bauduin,
- Chloé Le Roux,
- Romain Fouinneteau,
- Wilfried Berthe,
- Mathieu Berchel,
- Hélène Couthon and
- Paul-Alain Jaffrès
Beilstein J. Org. Chem. 2023, 19, 1299–1369, doi:10.3762/bjoc.19.96
- produced the final compound 2.8 (PAF) (Figure 2). A critical step in this synthesis scheme is the use of bromoethyl dichlorophosphate, prepared from POCl3 [65] and previously used for the synthesis of lecithin [66][67] and lecithin analogues [68], for the preparation of 2.6. It must be noted that a long
Graphical Abstract
Figure 1: Chemical structure of some natural ether lipids (ELs).
Figure 2: Synthesis of lyso-PAF and PAF from 1-O-alkylglycerol [64].
Figure 3: Synthesis of lyso-PAF from 1,3-benzylideneglycerol 3.1 [69].
Figure 4: A) Synthesis of the two enantiomers of octadecylglycerol (4.6 and 4.10) from ᴅ-mannitol (4.1); B) s...
Figure 5: Four-step synthesis of PAF 5.6 from (S)-glycidol [73].
Figure 6: Synthesis of 1-O-alkylglycerol A) from solketal, B) from ᴅ- or ʟ-tartaric acid and the intermediate ...
Figure 7: Synthesis of EL building blocks starting from substituted glycidol 7.1a–c [82].
Figure 8: Synthesis of PAF 8.5 by using phosphoramidite 8.2 [86].
Figure 9: Synthesis of oleyl-PAF 9.7 from ʟ-serine [88].
Figure 10: Synthesis of racemic analogues of lyso-PAF 10.8 and PAF 10.9 featuring a phenyl group between the g...
Figure 11: Synthesis of racemic deoxy-lyso-PAF 11.7 and deoxy-PAF 11.8 [91].
Figure 12: Synthesis of racemic thio-PAF 12.8 [93].
Figure 13: Racemic synthesis of 13.6 to illustrate the modification of the glycerol backbone by adding a methy...
Figure 14: Racemic synthesis of 14.5 as an illustration of the introduction of methyl substituents on the glyc...
Figure 15: Synthesis of functionalized sn-2-acyl chains of PC-EL; A) Steglich esterification or acylation reac...
Figure 16: Synthesis of racemic mc-PAF (16.3), a carbamate analogue of PAF [102].
Figure 17: A) Synthesis of (R)-17.2 and (S)-17.6 starting from (S)-solketal (17.1); B) synthesis of N3-PAF (17...
Figure 18: Modification of the phosphocholine polar head to produce PAF analogues [81].
Figure 19: Racemic PAF analogues 19.3 and 19.5 characterized by the absence of the phosphate group [107].
Figure 20: Synthesis of PIP3-PAF (20.7) [108].
Figure 21: Large-scale synthesis of C18-edelfosine (21.8) [116].
Figure 22: Synthesis of C16-edelfosine (22.10) starting from isopropylidene-ʟ-glyceric acid methyl ester (22.1...
Figure 23: Phosphocholine moiety installation by the use of chlorophosphite 23.2 as key reagent [119].
Figure 24: Synthesis of rac-1-alkyl-2-O-methylglycerol (AMG) [120].
Figure 25: Synthesis of stereocontrolled 1-alkyl-2-O-methyl glycerol 25.9 (AMG) from dimethyl ᴅ-tartrate [81].
Figure 26: A) Racemic synthesis of thioether 26.4 [129,130], B) structure of sulfone analogue 26.5 [129].
Figure 27: Stereocontrolled synthesis of C18-edelfosine thioether analogue 27.8 [118].
Figure 28: Synthesis of thioether 28.4 that include a thiophosphate function [134].
Figure 29: Synthesis of ammonium thioether 29.4 and 29.6 [135].
Figure 30: Synthesis of the N-methylamino analogue of edelfosine 30.6 (BN52211) [138].
Figure 31: Synthesis of 1-desoxy analogues of edelfosine; A) with a saturated alkyl chain; B) synthesis of the...
Figure 32: Stereocontrolled synthesis of edelfosine analogue (S)-32.8 featuring a C18:1 lipid chain [142].
Figure 33: Synthesis of edelfosine analogues with modulation of the lipid chain; A) illustration with the synt...
Figure 34: Synthesis of phospholipid featuring a carbamate function to link the lipid chain to the glycerol un...
Figure 35: Synthesis of sesquiterpene conjugates of phospho glycero ether lipids [148].
Figure 36: Racemic synthesis of methyl-substituted glycerol analogues 36.7 and 36.10: A) synthesis of diether ...
Figure 37: Racemic synthesis of ilmofosine (37.6) [155,156].
Figure 38: A) Stereoselective synthesis of 38.5 via a stereoselective hydroboration reaction; B) synthesis of ...
Figure 39: Racemic synthesis of SRI62-834 (39.6) featuring a spiro-tetrahydrofurane heterocycle in position 2 ...
Figure 40: Racemic synthesis of edelfosine analogue 40.5 featuring an imidazole moiety in sn-2 position [160].
Figure 41: Racemic synthesis of fluorine-functionalized EL: A) Synthesis of 41.6 and B) synthesis of 41.8 [161-163].
Figure 42: A) Synthesis of the β-keto-ester 42.6 that also features a decyl linker between the phosphate and t...
Figure 43: Synthesis of phosphonate-based ether lipids; A) edelfosine phosphonate analogue 43.7 and B) thioeth...
Figure 44: Enantioselective synthesis of phosphonates 44.3 and 44.4 [171].
Figure 45: Racemic synthesis of phosphinate-based ether lipid 45.10 [172].
Figure 46: Racemic synthesis of edelfosine arsonium analogue 46.5 [173].
Figure 47: Synthesis of edelfosine dimethylammonium analogue 47.2 [118].
Figure 48: Synthesis of rac-C18-edelfosine methylammonium analogue 48.4 [176].
Figure 49: A) Synthesis of edelfosine N-methylpyrrolidinium analogue 49.2 or N-methylmorpholinium analogue 49.3...
Figure 50: A) Synthesis of edelfosine’s analogue 50.4 with a PE polar group; B) illustration of a pyridinium d...
Figure 51: A) Synthesis of 51.4 featuring a thiazolium cationic moiety; B) synthesis of thiazolium-based EL 51...
Figure 52: Synthesis of cationic ether lipids 52.3, 52.4 and 52.6 [135,183].
Figure 53: Synthesis of cationic carbamate ether lipid 53.5 [184].
Figure 54: Synthesis of cationic sulfonamide 54.5 [185].
Figure 55: Chemical structure of ONO-6240 (55.1) and SRI-63-119 (55.2).
Figure 56: Synthesis of non-ionic ether lipids 56.2–56.9 [188].
Figure 57: Synthesis of ether lipid conjugated to foscarnet 57.6 [189].
Figure 58: A) Synthesis of ether lipid conjugated to arabinofuranosylcytosine; B) synthesis of AZT conjugated ...
Figure 59: Synthesis of quercetin conjugate to edelfosine [191].
Figure 60: Synthesis of 60.8 (Glc-PAF) [194].
Figure 61: A) Synthesis of amino ether lipid 61.7 functionalized with a rhamnose unit and its amide analogue 6...
Figure 62: A) Synthesis of glucose ether lipid 62.4; B) structure of ether lipid 62.5 possessing a maltose uni...
Figure 63: A) Synthesis of glucuronic methyl ester 63.8; B) structure of cellobiose 63.9 and maltose 63.10 ana...
Figure 64: A) Synthesis of maltosyl glycerolipid 64.7; B) structure of lactose analogue 64.8 prepared followin...
Figure 65: A) Asymmetric synthesis of the aglycone moiety starting from allyl 4-methoxyphenyl ether; B) glycos...
Figure 66: A) Synthesis of ohmline possessing a lactose moiety. B) Structure of other glyco glycero lipids pre...
Figure 67: A) Synthesis of lactose-glycerol ether lipid 67.5; B) analogues possessing a maltose (67.6) or meli...
Figure 68: Synthesis of digalactosyl EL 68.6, A) by using trityl, benzyl and acetyl protecting groups, B) by u...
Figure 69: A) Synthesis of α-ohmline; B) structure of disaccharide ether lipids prepared by using similar meth...
Figure 70: Synthesis of lactose ether lipid 70.3 and its analogue 70.6 featuring a carbamate function as linke...
Figure 71: Synthesis of rhamnopyranoside diether 71.4 [196].
Figure 72: Synthesis of 1-O-hexadecyl-2-O-methyl-3-S-(α-ᴅ-1'-thioglucopyranosyl)-sn-glycerol (72.5) [225].
Figure 73: A) Preparation of lipid intermediate 73.4; B) synthesis of 2-desoxy-C-glycoside 73.10 [226].
Figure 74: Synthesis of galactose-pyridinium salt 74.3 [228].
Figure 75: Synthesis of myo-inositol derivative Ino-C2-PAF (75.10) [230].
Figure 76: A) Synthesis of myo-inositol phosphate building block 76.7; B) synthesis of myo-inositolphosphate d...
Figure 77: A) Synthesis of phosphatidyl-3-desoxy-inositol 77.4; B) synthesis of phosphono-3-desoxyinositol 77.9...
Figure 78: A) Structure of diether phosphatidyl-myo-inositol-3,4-diphosphate 78.1; B) synthesis of phosphatidy...
Figure 79: A) Synthesis of diether-phosphatidyl derivative 79.4 featuring a hydroxymethyl group in place of a ...
Figure 80: Synthesis of Glc-amine-PAF [78].
Figure 81: Synthesis of glucosamine ether lipid 81.4 and its analogues functionalized in position 3 of the ami...
Figure 82: Synthesis of fully deprotected aminoglucoside ether lipid 82.5 [246].
Figure 83: Synthesis of C-aminoglycoside 83.12 using Ramberg–Bäcklund rearrangement as a key step [250].
Figure 84: A) List of the most important glyco lipids and amino glyco lipids included in the study of Arthur a...
Figure 85: Synthesis of mannosamine ether lipid 85.6 [254].
Figure 86: A) Synthesis of glucosamine ether lipids with a non-natural ʟ-glucosamine moiety; B) synthesis of e...
Figure 87: A) Structure of the most efficient anticancer agents 87.1–87.4 featuring a diamino glyco ether lipi...
Figure 88: A) Synthesis of diamino glyco ether lipid 87.4; B) synthesis of bis-glycosylated ether lipid 88.10 [256]....
Figure 89: Synthesis of triamino ether lipid 89.4 [260].
Figure 90: Synthesis of chlorambucil conjugate 90.7 [261].
Figure 91: Three main methods for the preparation of glycerol ether lipid 91.3; A) from solketal and via a tri...
Figure 92: Four different methods for the installation of the phosphocholine polar head group; A) method using...
Figure 93: Illustration of two methods for the installation of saccharides or aminosaccharides; A) O-glycosyla...
Discrimination of β-cyclodextrin/hazelnut (Corylus avellana L.) oil/flavonoid glycoside and flavonolignan ternary complexes by Fourier-transform infrared spectroscopy coupled with principal component analysis
- Nicoleta G. Hădărugă,
- Gabriela Popescu,
- Dina Gligor (Pane),
- Cristina L. Mitroi,
- Sorin M. Stanciu and
- Daniel Ioan Hădărugă
Beilstein J. Org. Chem. 2023, 19, 380–398, doi:10.3762/bjoc.19.30
- , cyclosporine A and polyvinyl alcohol, ketoprofen and phospholipids, dihydroartemisinin and lecithin, cefixime and ʟ-arginine, flurbiprofen and naproxen/ketoprofen/ethenzamide [50][51][52][53][54][55][56][57][58][59]. Fourier-transform infrared spectroscopy (FTIR) is a very fast, nondestructive and cheap method
Graphical Abstract
Figure 1: Hypothetical interactions between the β-cyclodextrin host and guest molecules (flavonoid glycoside/...
Figure 2: Superposition of the FTIR spectra for the β-cyclodextrin/Corylus avellana oil/hesperidin ternary co...
Figure 3: Superposition of the FTIR spectra for the β-cyclodextrin/Corylus avellana oil/hesperidin ternary co...
Figure 4: PC2 versus PC1 scores plot from the FTIR–PCA analysis of the flavonoid glycoside and flavonolignan ...
Figure 5: PC2 versus PC1 scores plot from the FTIR–PCA analysis of the β-CD/hazelnut oil/flavonoid ternary co...
Figure 6: PC2 versus PC1 scores plot from the FTIR–PCA analysis of the β-CD/hazelnut oil/flavonoid ternary co...
Figure 7: PC2 versus PC1 scores plot from the FTIR–PCA analysis of the β-CD/hazelnut oil/flavonoid ternary co...
Figure 8: PC3 versus PC1 scores plot from the FTIR-PCA analysis of the β-CD/hazelnut oil/flavonoid ternary co...
Figure 9: PC3 versus PC2 scores plot from the FTIR–PCA analysis of the β-CD/hazelnut oil/flavonoid ternary co...
Figure 10: PC2 versus PC1 loadings plot from the FTIR–PCA analysis of the β-CD/hazelnut oil/flavonoid ternary ...
Figure 11: PC3 versus PC1 loadings plot from the FTIR–PCA analysis of the β-CD/hazelnut oil/flavonoid ternary ...
Figure 12: Eigenvalues of the correlation matrix from the FTIR–PCA analysis of the β-CD/hazelnut oil/flavonoid...
Dirhamnolipid ester – formation of reverse wormlike micelles in a binary (primerless) system
- David Liese,
- Hans Henning Wenk,
- Xin Lu,
- Jochen Kleinen and
- Gebhard Haberhauer
Beilstein J. Org. Chem. 2020, 16, 2820–2830, doi:10.3762/bjoc.16.232
- (respectively the one-dimensional growth) often requires the use of the correct amount of a primer [14]. Lecithin is the most prominent example of molecules forming reverse wormlike micelles [15][16][17]. The rheological properties of many oils can be fine-tuned by worm-like micelles in a more convenient way as
- compared to polymers and also the sensorial properties (like stringiness) are more pleasant [18]. However, the quality of the lecithin needs to be very high so that reverse wormlike micelles can be formed [19] and the amount of the primer needs to be well balanced as was described by Shchipunov when
- studying a lecithin/water system [20]. Gemini (bola) surfactants are a class of amphiphiles that has recently attracted a lot of attention [21][22][23][24][25]. They are made of two (or more) head groups that are connected by a spacer, that can be rigid or of variable length. In the present contribution we
Graphical Abstract
Figure 1: Chemical structure of dirhamnolipid 1.
Scheme 1: Synthesis of the dirhamnolipid esters and the chemical structure of 7.
Figure 2: Solubility of the dirhamnolipid esters in various solvents (+ = soluble, − = insoluble, G = gel).
Figure 3: Phase transition temperature for the dirhamnolipid esters in toluene while heating (TGS, blue) and ...
Figure 4: Amplitude sweep: double logarithmic plot of the dynamic moduli against the amplitude (deformation) ...
Figure 5: Frequency sweep: double logarithmic plot of the dynamic moduli against the frequency for the dirham...
Figure 6: Double logarithmic plot of (a) the plateau modulus G0 and (b) the relaxation time τR against the co...
Figure 7: Semilogarithmic plot of (a) G0/G''min, (b) η0, and (c) τR against the inverse absolute temperature ...
Figure 8: Polarized optical microscopy (POM) images of the 2/toluene system (5 wt %) with crossed polarizers ...
Figure 9: Schematic representation of the formation of RWLM by dirhamnolipid esters.
A study on the inhibitory mechanism for cholesterol absorption by α-cyclodextrin administration
- Takahiro Furune,
- Naoko Ikuta,
- Yoshiyuki Ishida,
- Hinako Okamoto,
- Daisuke Nakata,
- Keiji Terao and
- Norihiro Sakamoto
Beilstein J. Org. Chem. 2014, 10, 2827–2835, doi:10.3762/bjoc.10.300
- : Micelle formation of cholesterol with lecithin and bile salts is a key process for intestinal absorption of lipids. Some dietary fibers commonly used to reduce the lipid content in the body are thought to inhibit lipid absorption by binding to bile salts and decreasing the lipid solubility. Amongst these
- of other dietary fibers. To identify this mechanism, we investigated the interaction of α-CD with lecithin and bile salts, which are essential components for the dissolution of cholesterol in the small intestine, and the effect of α-CD on micellar solubility of cholesterol. Results: α-CD was added to
- Fed-State Simulated Intestinal Fluid (FeSSIF), and precipitation of a white solid was observed. Analytical data showed that the precipitate was a lecithin and α-CD complex with a molar ratio of 1:4 or 1:5. The micellar solubility of cholesterol in the mixture of FeSSIF and α-CD was investigated, and
Graphical Abstract
Figure 1: Image of the FeSSIF and other buffers with and without α-CD. α-CD was added into the FeSSIF or othe...
Figure 2: Effect of α-CD on the concentration of lecithin and taurocholate in the FeSSIF. After adding each a...
Figure 3: Concentration of α-CD in the FeSSIF. The experimental conditions were the same as those described i...
Figure 4: Time-dependent relationship between decreases in lecithin and α-CD. The experimental conditions wer...
Figure 5: Amounts of lecithin and α-CD precipitates. The amounts of lecithin and α-CD precipitated were calcu...
Figure 6: Dose-dependent decrease of the micellar cholesterol solubility in the FeSSIF by α-CD. After additio...
Figure 7: Effect of several dietary fibers on the micellar cholesterol solubility in FeSSIF. Various amounts ...
Figure 8: Hypothetical scheme for the inhibitory action of α-CD on the micellar cholesterol solubility in int...
Encapsulation of biocides by cyclodextrins: toward synergistic effects against pathogens
- Véronique Nardello-Rataj and
- Loïc Leclercq
Beilstein J. Org. Chem. 2014, 10, 2603–2622, doi:10.3762/bjoc.10.273
- . Classically, the inactivation of quaternary ammonium biocides is performed with mixtures of polyoxyethylene (20) sorbitan monooleate (Tween 80) and lecithin which trap the biocidal agents inside the micelles formed by the neutralization agents. In his paper, Simpson showed that the neutralization can be made
Graphical Abstract
Scheme 1: Principle of resistance mechanisms through selection of the most resistant micro-organism.
Figure 1: Chemical structure of carbendazim.
Scheme 2: Chemical structure of benomyl and its decomposition in aqueous solution.
Figure 2: Chemical structure of enilconazole.
Figure 3: Chemical structure of chloramidophos.
Scheme 3: The complex problem of pentachlorophenol (PCP) degradation.
Figure 4: Chemical structure of DCPE.
Figure 5: Chemical structures of some biocides used in [59].
Figure 6: Chemical structure of miconazole nitrate.
Figure 7: Chemical structures of triclosan and butylparaben.
Figure 8: Chemical structure of ciprofloxacin hydrochloride.
Figure 9: Chemical structure of benzethonium chloride.
Figure 10: Chemical structure of benzalkonium chlorides.
Scheme 4: Multiple equilibria of CD with benzalkonium chloride (BZK) and fluorometholone.
Scheme 5: Competition between co-micellization and biocidal activity observed for didecyldimethylammonium chl...
Scheme 6: Proposed antimicrobial mechanism of encapsulated didecyldimethylammonium chloride by CDs: (1) diffu...
Scheme 7: Inhibition of co-micellization process observed for didecyldimethylammonium chloride, octaethyleneg...
Scheme 8: Schematic representation of biocide release from a chemically cross-linked CD network.
Scheme 9: Proposed Trojan horse mechanism of silver nanoparticles capped by β-CD.
Scheme 10: Proposed mechanism of copper nanoparticles immobilized on carbon nanotube and embedded in water-ins...
Scheme 11: Advantages and drawback of the physicochemical and biopharmaceutical properties of CDs/biocides inc...
